ORIGINAL ARTICLE

Increased risk of mycobacterial infections associated with anti-rheumatic medications

Sarah K Brode,1,2,3 Frances B Jamieson,4,5 Ryan Ng,6 Michael A Campitelli,6 Jeffrey C Kwong,4,6,7,8 J Michael Paterson,6,9,10 Ping Li,6 Alex Marchand-Austin,4 Claire Bombardier,9,11 Theodore K Marras1,3

ABSTRACT

Rationale Anti-tumour necrosis factor (TNF) agents and other anti-rheumatic medications increase the risk of TB in rheumatoid arthritis (RA). Whether they increase the risk of infections with nontuberculous mycobacteria (NTM) is uncertain.

Objectives To determine the effect of anti-TNF therapy and other anti-rheumatic drugs on the risk of NTM disease and TB in older patients with RA.

Methods Population-based nested case–control study among Ontario seniors aged ≥67 years with RA who were prescribed at least one anti-rheumatic medication between 2001 and 2011. We identified cases of TB and NTM disease microbiologically and identified drug exposures using linked prescription drug claims. We estimated ORs using conditional logistic regression, controlling for several potential confounders.

Measurements and main results Among 56,269 older adults with RA, we identified 37 cases of TB and 211 cases of NTM disease; each case was matched to up to 10 controls. Individuals with TB or NTM disease were both more likely to be using anti-TNF therapy (compared with non-use); adjusted ORs (95% CIs) were 5.04 (1.27 to 20.0) and 2.19 (1.10 to 4.37), respectively. Exposure to leflunomide and other anti-rheumatic drugs with high immunosuppressing potential also were associated with both TB and NTM disease, while oral corticosteroids and hydroxychloroquine were associated with NTM disease.

Conclusions Anti-TNF use is associated with increased risk of both TB and NTM disease, but appears to be a relatively greater risk for TB. Several other anti-rheumatic drugs were also associated with mycobacterial infections.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting approximately 1% of all people.1 Over a decade ago, treatment for this disabling condition was revolutionised by the ‘biological’ agents, including anti-tumour necrosis factor (TNF) agents. This class of medications reduces the action of TNF-α, a pro-inflammatory cytokine that causes synovitis in RA, but also plays a key role in the immune response to mycobacteria.

Numerous studies from around the world have demonstrated that anti-TNF therapy is associated with an increased risk of TB.2–4 However, patients with RA also are at higher risk for TB than the general population,5 perhaps due to both anti-rheumatic medications6 and immune dysregulation intrinsic to the disease.6 The association between nontuberculous mycobacterial (NTM) disease, RA and immunosuppressive medications is less clear. NTM may act as opportunistic pathogens, exploiting airway mucosal7 or generalised immunodeficiency states,8 and so may pose a risk to patients with RA. Clinical confusion often arises around NTM disease as a mimic of TB; the former is more common in high-income countries and more difficult to treat. It is therefore important to determine if patients with RA using immunosuppressives are at increased risk of NTM, but few studies have examined this issue.9 In Ontario, Canada, persons with RA were found to have a twofold risk of NTM disease and TB compared with persons without RA, and experienced NTM disease far more commonly than TB.10 The main objective of this study was to quantify the risk of NTM isolation/disease and TB associated with anti-TNF use in patients with RA.

METHODS

Study population and setting

We performed a population-based nested case–control study using linked health administrative
patients from the health administrative databases with University Health Network (11-1018-AE) and Sunnybrook back for prescription drug use. Ethics approvals were from the until the earliest of emigration, death or 31 December 2011.

anti-inflammatory drug (NSAID). Cohort patients were followed until the earliest of emigration, death or 31 December 2011. Ontario is Canada’s most populous province (13.5 million in 2013), is ethnically diverse and has a single-payer healthcare system providing universal access to hospital care, physician services and prescription drugs to adults aged ≥65 years. We included only individuals aged ≥67 years to allow a 2-year look-back for prescription drug use. Ethics approvals were from the Research Ethics Boards at the University of Toronto (26090), University Health Network (11-1018-AE) and Sunnybrook Health Sciences Centre, all in Toronto, Canada.

**Data sources**

We used the Canadian Institute for Health Information’s Discharge Abstract Database for diagnostic information recorded during admissions to acute care hospitals and the Ontario Health Insurance Plan physician billing claims database for patient services to define RA and comorbidities. RA was identified using a validated diagnostic code algorithm, comprising ≥1 hospitalisation with a diagnosis code for RA, or three physician claims with RA diagnosis codes in ≤2 years (≥1 claim by a specialist). This algorithm has a sensitivity of 78% and a specificity of 100%. Prescription drug exposures were identified using the Ontario Drug Benefit (ODB) database, which contains records of outpatient prescription medications dispensed to Ontarians aged ≥65 years. Demographic information was obtained from the Ontario Registered Persons Database. Cases of mycobacterial infection were identified by linking individual patient records from the health administrative databases with the Public Health Ontario Laboratory database, which includes isolates from 100% of TB cases and approximately 95% of NTM cases in Ontario. Microbiological methods are described in online supplementary appendix 1.

**Identification of case and control patients**

Case patients were defined as follows: (a) TB, any culture positive for *Mycobacterium tuberculosis* complex organisms; (b) NTM isolation, any culture positive for NTM; and (c) NTM disease, NTM isolation from ≥2 sputum or ≥1 bronchoscopy or lung biopsy specimen (a validated microbiological surrogate for pulmonary NTM disease with a positive predictive value ranging between 69.5% and 90% in general populations and 100% in patients with RA on anti-TNF therapy) or any positive culture from a normally sterile body site, including pleura. We excluded individuals with NTM isolated at any time before cohort entry (n=317) or prior TB (n=31) within the past <18 months. We also excluded all *Mycobacterium gordonae* isolations as likely contamination.

For cases, the index date was defined as the date the first positive mycobacterial culture was isolated. Each case was matched to up to 10 controls within the cohort of patients with RA on the index date according to age (±365 days), sex, year of cohort entry and duration of RA (within quartile: 0–3 years, 4–8 years, 9–13 years or ≥14 years). Because of the large sample available to us, we chose to match up to 10 controls, to increase precision of results. When fewer than 10 controls could be matched to a case, we used only the controls that could be matched, without changing the matching algorithm. Cases could serve as controls before becoming a case, but controls were sampled without replacement. Controls were assigned the index date of their corresponding case.

**Drug exposure definitions**

The anti-TNF agents we studied were infliximab, adalimumab and etanercept. All non-biological anti-rheumatic drugs paid for by the ODB Program during the study period were also studied (oral corticosteroids, methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclophosphamide, azathioprine, ciclosporin, mycophenolate, chlorambucil, gold, penicillamine and NSAIDs). Because of a potential association between gastrointestinal reflux disease (GORD) and pulmonary NTM infection, proton pump inhibitor (PPI) use was studied for NTM outcomes, but not TB. Individuals were considered exposed to an injectable medication starting on the prescription date and ending after five half-lives. Individuals were considered exposed to an oral medication (all medications other than anti-TNF agents) starting on the prescription date and ending after the number of days supplied on the prescription claim. For the primary analysis examining anti-TNF use, current use was defined as end of exposure ≤6 months prior to index date, past use was defined as end of exposure 6–18 months prior to index date and no use was defined as never use or end of exposure >18 months prior to index date. ‘Current use’ extended 6 months beyond exposure to allow for delay after infection date to symptom onset, physician’s request for specimen collection, collection of the specimen and specimen receipt in the laboratory. Others have defined ‘current use’ as 90 days beyond exposure, but found no significant difference between a 90-day and 6-month definition. We included a ‘past use’ exposure category because of the indolent nature of NTM infections, assuming that many patients experience a >6-month delay between infection and symptom onset/diagnosis. For the secondary analysis examining other anti-rheumatic medications, current use was defined as above, and non-current use was defined as non-use or end of exposure >6 months prior to index date. Corticosteroid dose was computed based upon the most recently filled prescription and converted to average daily prednisone equivalents: (1) low dose, ≤9 mg/day; (2) medium dose, 10–19 mg/day and (3) high dose, ≥20 mg/day.

**Statistical analysis**

We used conditional logistic regression to estimate the crude and adjusted ORs and 95% CIs to quantify associations between TB, NTM isolation, NTM disease and exposure to specific anti-rheumatic drugs. The primary analysis compared current and past users versus non-users of anti-TNF agents. The preplanned secondary analysis compared current versus non-current users of other anti-rheumatic drugs. The multivariable model was adjusted for covariates possibly associated with TB or NTM, including income, rurality of patient residence, presence of extra-articular features of RA (grouped into lung, skin and other), other anti-rheumatic medication use, aggregated diagnostic groups (ADGs) (a general measure of comorbidity) and comorbidities. ADGs were determined from inpatient and outpatient health records from 2 years prior to the index date, using the Johns Hopkins Adjusted Clinical Group Case-Mix System. Comorbidities included diabetes and chronic kidney disease for TB, and asthma, COPD and GORD for NTM. Comorbidities were identified using validated algorithms, looking back from cohort entry to 1 April 1991 (the earliest date available). If definitions were not met, comorbidities were assumed to be absent. Because data capture was complete for
our variables, no allowance for handling of missing data was required. Analyses were performed using SAS V9.3 (SAS Institute, Cary, North Carolina, USA). All tests were two-tailed with a type 1 error (α) rate of 5%.

RESULTS
We identified 61,827 elderly adults with RA during the study period (figure 1). We excluded 5558 because they did not fill at least one prescription for a DMARD, biological or NSAID, leaving 56,269 individuals. Within this group, we identified 37 cases of TB who we matched to 363 controls, and 211 cases of NTM disease who we matched to 2071 controls. Findings regarding NTM isolation are presented in online supplementary appendix 2, and NTM species causing disease are presented in online supplementary appendix 3. TB cases were more likely to live in urban settings and have pulmonary extra-articular RA, overall comorbidities (higher ADGs), chronic kidney disease and diabetes than controls (table 1).26 NTM disease cases were more likely to live in urban settings, have pulmonary extra-articular RA, overall comorbidities, asthma, COPD and GORD than controls.

Anti-TNF use
Current anti-TNF users had significantly increased risk of TB compared with non-users (crude OR=6.44 (2.02 to 20.6), adjusted OR=5.04 (1.27 to 20.0)) (table 2). Current anti-TNF users also had significantly increased risk of NTM disease compared with non-users (crude OR=2.42 (1.34 to 4.37), adjusted OR=2.19 (1.10 to 4.37)), but the risk magnitude was numerically less than for TB. There were no anti-TNF past users among TB cases. Past anti-TNF use was not associated with NTM disease. Regarding site of infection, 89% of NTM disease was pulmonary, without significant difference between anti-TNF users (87%) and non-users (89%). Eighty-one per cent of TB was pulmonary, without significant difference between anti-TNF users (83%) and non-users (81%).

Other anti-rheumatic medication use
Several non-biological anti-rheumatic medications were infrequently used among both TB and NTM disease cases, and so were grouped into classes with high or low immunosuppressing potential based on clinical judgement (table 2).

Many anti-rheumatic medications were associated with an increased risk of TB and NTM disease in unadjusted analyses. After full adjustment, only leflunomide (OR=4.02 (1.08 to 15.0)) and drugs classed as highly immunosuppressive (OR=23.0 (2.88 to 184)) were associated with an increased risk of TB (table 2). High-dose oral corticosteroids (OR=1.60 (1.02 to 2.52)), leflunomide (OR=2.74 (1.59 to 4.70)), hydroxychloroquine (OR=1.62 (1.13 to 2.33)) and drugs classed as highly immunosuppressive (OR=2.92 (1.26 to 6.79)) were associated with an increased risk of NTM disease after adjustment (table 2).

DISCUSSION
In our cohort of 56,269 older adults with RA, current users of anti-TNF agents, were at increased risk of both TB and NTM disease. Because of higher rates of NTM disease in the RA cohort overall, there were more cases of NTM disease than TB in anti-TNF users, but the magnitude of the risk was larger for TB than for NTM disease (adjusted OR: 5.04 vs 2.19). Several other anti-rheumatic medications also increased the risk of TB and NTM disease to a similar magnitude as anti-TNF agents.

Several studies have reported an increased risk of TB in anti-TNF users;2–4 however, few examined the association between anti-TNF agents and NTM disease. The most rigorous of the latter group was a cohort study among members of one health maintenance organization (HMO) in California.8 In that study, incidence rates of TB and NTM in anti-TNF users were calculated, as were rates in the general HMO population and the unexposed RA population. Rates of both NTM disease and TB were higher in anti-TNF users than unexposed patients with RA, and NTM was more common than TB in anti-TNF users. However, this study did not adjust for potential confounders when comparing risks between exposed and unexposed patients. In addition, members of an HMO may not be representative of the general population. The findings of our population-based study expand upon their results by confirming that the risks of mycobacterial infections are increased in anti-TNF users compared with non-users, even after adjusting for several potential confounders.

Another interesting finding in our study was the increased risks of both TB and NTM disease associated with several other anti-rheumatic drugs. Previous work has shown an increased risk of TB with oral corticosteroids, methotrexate, leflunomide and ciclosporin.27 We also found an increased risk of TB with leflunomide and drugs with high immunosuppressing potential (including ciclosporin). However, after full adjustment, there was no association between oral corticosteroid or methotrexate use and TB in our study, perhaps due to the rarity of TB in our cohort.

Regarding NTM disease, there has been limited research on associations with non-biological anti-rheumatic drugs. One case–control study showed an increased risk of NTM associated with use of oral corticosteroids and immunomodulatory drugs, defined as biological and non-biological DMARDs.28 Case series have also suggested an increased risk of NTM in stem cell and solid organ transplantation recipients29 likely at least partially due to immunosuppressant use. However, no prior study has examined the risk of NTM disease associated with use of different anti-rheumatic drugs. Our findings suggest that several anti-rheumatic drugs increase the risk of NTM disease. Somewhat surprisingly, the risk of NTM associated with leflunomide and drugs classed as highly immunosuppressive was actually of larger magnitude than the risk with anti-TNF agents, although CIs overlapped.

The difference in anti-TNF-associated risk estimates between TB and NTM disease is intriguing. The larger OR for TB could be explained by imprecise risk estimates in the TB group due to the small number of TB cases, or alternatively, to differences in

---

70:677–682. doi:10.1136/thoraxjnl-2014-206470 679

Figure 1 Study population. TB cases defined by any culture positive for Mycobacterium tuberculosis complex organisms; NTM disease cases defined by ≥2 sputum, or ≥1 bronchoscopy or lung biopsy specimen, or any positive culture from a normally sterile body site, including pleura. DMARD, disease modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug; NTM, nontuberculous mycobacterial; RA, rheumatoid arthritis. RA treatment includes at least one filled prescription for a DMARD, biological or NSAID.
increased rates of NTM, and immunosuppression is a risk factor might identify pulmonary NTM infections that require patients with RA before initiating high-risk anti-rheumatic drugs. Anti-TNF and other high-risk anti-rheumatic drugs may also screen patients with RA for NTM infection prior to practice in Ontario, fails to detect a substantial proportion of LTBI. Discordance between tests suggests that testing for LTBI with a single test (either TST or IGRA), likely the most common practice, is of uncertain adequacy. Major discordance between tests suggests that testing for LTBI with a single test (either TST or IGRA), likely the most common practice in Ontario, fails to detect a substantial proportion of LTBI.

The rationale behind screening for and treating LTBI prior to anti-TNF therapy is clear and reduces the risk of TB disease. Screening patients with RA for NTM infection prior to anti-TNF and other high-risk anti-rheumatic drugs may also provide benefit. From the RA perspective, patients have increased rates of NTM, and immunosuppression is a risk factor for NTM disease, which may promote progression of pre-existing unrecognised infection. From the NTM disease perspective, this infection significantly impairs quality of life, and its treatment is challenging, with low cure rates and high rates of drug toxicity. Considering the possibility of NTM infection in patients with RA before initiating high-risk anti-rheumatic drugs might identify pulmonary NTM infections that require antimicrobial therapy, closer monitoring and/or avoidance of high-risk immunosuppressive drugs. NTM screening in this setting may comprise a pulmonary and systemic symptom review and chest radiograph, both likely performed before initiating immunosuppression. Further testing might be considered based on the results of history and radiography. Current evidence may not yet be sufficient to recommend universal screening, but we think that this issue should be explored.

This study has several limitations. An important limitation is the absence of individual-level data on rheumatic disease activity, preventing separation of the effect of disease activity from anti-rheumatic drugs. Rheumatic disease activity, indicated by extra-articular RA and NSAID/cyclooxygenase (COX)-inhibitor use, increases the risk of infections. Although we adjusted for these factors, this proxy is of uncertain adequacy. It is therefore possible that the observed associations between antimicrobial therapy and certain rheumatic drugs and mycobacterial infections are more related to rheumatic disease activity than they are to medication use. This might explain the observed association between NTM disease and hydroxychloroquine (OR: 1.62 (1.13 to 2.33)), a drug not typically associated with infection, and the lack of association with methotrexate (OR: 1.31 (0.93 to 1.86)), a drug known to increase risk of infections.

Most Ontarians with RA who are on DMARDs other than methotrexate likely have more severe disease activity than those who only receive methotrexate because the Canadian Rheumatology Association recommends methotrexate as the first-line DMARD for the treatment of RA.

Another study limitation is the reliance on health administrative data to identify drug exposure. Outpatient medication adherence cannot be confirmed, and inpatient medication use is unavailable, so medication exposures could be over- or underestimated. Also, we defined TB and NTM disease based on microbiological data. Microbiological-based outcome definitions have excellent positive predictive value for TB (100%), but by ignoring clinically diagnosed culture-negative cases, their sensitivity is reduced (55%–79%). Regarding NTM disease, our microbiological-based outcome definition has shown good

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Cases N=37</th>
<th>Controls N=363</th>
<th>SDMt p Value</th>
<th>Cases N=211</th>
<th>Controls N=2071</th>
<th>SDMt p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>22 (59)</td>
<td>220 (61)</td>
<td>0.02 0.89</td>
<td>147 (70)</td>
<td>1452 (70)</td>
<td>0.01 0.89</td>
</tr>
<tr>
<td>Age, mean±SD</td>
<td>75.6±5.7</td>
<td>76.2±7.1</td>
<td>0.05 0.79</td>
<td>78.6±5.0</td>
<td>76.1±5.8</td>
<td>0.03 0.67</td>
</tr>
<tr>
<td>RA duration (years), mean±SD</td>
<td>8.1±5.6</td>
<td>8.5±5.5</td>
<td>0.09 0.62</td>
<td>8.9±5.3</td>
<td>8.9±5.2</td>
<td>0.00 1.00</td>
</tr>
<tr>
<td>Income above median</td>
<td>20 (54)</td>
<td>206 (57)</td>
<td>0.05 0.75</td>
<td>128 (61)</td>
<td>1193 (58)</td>
<td>0.06 0.39</td>
</tr>
<tr>
<td>Rural residency</td>
<td>0 (0)</td>
<td>53 (15)</td>
<td>0.43 0.01</td>
<td>13 (6)</td>
<td>307 (15)</td>
<td>0.25 &lt;0.001</td>
</tr>
<tr>
<td>Extra-articular RA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>6 (16)</td>
<td>25 (7)</td>
<td>0.35 0.04</td>
<td>44 (21)</td>
<td>143 (7)</td>
<td>0.51 &lt;0.001</td>
</tr>
<tr>
<td>Skin</td>
<td>≤5 (≤14)</td>
<td>37 (10)</td>
<td>0.27 0.01</td>
<td>28 (13)</td>
<td>202 (10)</td>
<td>0.12 0.11</td>
</tr>
<tr>
<td>Other</td>
<td>≤5 (≤14)</td>
<td>6 (2)</td>
<td>0.27 0.12</td>
<td>≤5 (≤3)</td>
<td>32 (2)</td>
<td>0.03 0.70</td>
</tr>
<tr>
<td>ADGs, mean±SD</td>
<td>11.8±3.5</td>
<td>8.9±3.5</td>
<td>&lt;0.001</td>
<td>11.2±3.2</td>
<td>8.8±3.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Asthma</td>
<td>57 (16)</td>
<td>61 (16)</td>
<td>0.01 0.93</td>
<td>89 (42)</td>
<td>374 (18)</td>
<td>0.61 &lt;0.001</td>
</tr>
<tr>
<td>COPD</td>
<td>11 (30)</td>
<td>99 (27)</td>
<td>0.05 0.75</td>
<td>135 (64)</td>
<td>616 (30)</td>
<td>0.75 &lt;0.001</td>
</tr>
<tr>
<td>GORD</td>
<td>11 (30)</td>
<td>92 (25)</td>
<td>0.10 0.56</td>
<td>61 (29)</td>
<td>493 (24)</td>
<td>0.12 0.10</td>
</tr>
<tr>
<td>CKD</td>
<td>6 (16)</td>
<td>37 (10)</td>
<td>0.18 0.29</td>
<td>26 (12)</td>
<td>211 (10)</td>
<td>0.07 0.33</td>
</tr>
<tr>
<td>Diabetes</td>
<td>9 (24)</td>
<td>70 (19)</td>
<td>0.13 0.46</td>
<td>49 (23)</td>
<td>509 (25)</td>
<td>0.03 0.66</td>
</tr>
</tbody>
</table>

*Values are the number of patients (%) unless otherwise indicated.

1SDM, standardised difference of the mean (mean difference as a percentage of the average SD) wherein >0.1 (10%) implies a meaningful imbalance between groups. ADGs, aggregated diagnostic groups; CKD, chronic kidney disease; GORD, gastro-oesophageal reflux disease; NTM, nontuberculous mycobacterial; RA, rheumatoid arthritis; SDM, standardised difference of the mean.
<table>
<thead>
<tr>
<th>Exposure</th>
<th>TB cases N=37</th>
<th>TB controls N=363</th>
<th>Crude OR (95% CI) p Value</th>
<th>Adjusted* OR (95% CI) p Value</th>
<th>NTM cases N=211</th>
<th>NTM controls N=2071</th>
<th>Crude OR (95% CI) p Value</th>
<th>Adjusted* OR (95% CI) p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-TNF use</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No use</td>
<td>31 (84)</td>
<td>350 (96)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
<td>194 (92)</td>
<td>1997 (96)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Past use</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>NA</td>
<td>NA</td>
<td>NR</td>
<td>7 (0.3)</td>
<td>2.94 (0.61 to 14.2)</td>
<td>0.18</td>
</tr>
<tr>
<td>Current use</td>
<td>6 (16)</td>
<td>13 (4)</td>
<td>6.44 (2.02 to 20.6)</td>
<td>0.002</td>
<td>5.04 (1.27 to 20.0)</td>
<td>0.02</td>
<td>2.42 (1.34 to 4.37)</td>
<td>0.003</td>
</tr>
<tr>
<td>Oral corticosteroids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-current use</td>
<td>15 (40)</td>
<td>242 (66)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
<td>106 (50)</td>
<td>1401 (68)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Low dose</td>
<td>9 (24)</td>
<td>57 (16)</td>
<td>2.45 (1.04 to 5.81)</td>
<td>0.04</td>
<td>1.63 (0.60 to 4.44)</td>
<td>0.34</td>
<td>1.28 (0.84 to 1.93)</td>
<td>0.25</td>
</tr>
<tr>
<td>Mod dose</td>
<td>6 (16)</td>
<td>23 (6)</td>
<td>3.80 (1.33 to 10.8)</td>
<td>0.01</td>
<td>2.53 (0.55 to 11.6)</td>
<td>0.23</td>
<td>2.97 (1.90 to 4.63)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>High dose</td>
<td>7 (19)</td>
<td>41 (11)</td>
<td>2.72 (1.04 to 7.09)</td>
<td>0.04</td>
<td>2.73 (0.81 to 9.20)</td>
<td>0.11</td>
<td>3.24 (2.18 to 4.84)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Methotrexate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-current use</td>
<td>25 (68)</td>
<td>256 (70)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
<td>136 (64)</td>
<td>1431 (69)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Current use</td>
<td>12 (32)</td>
<td>107 (30)</td>
<td>1.19 (0.57 to 2.48)</td>
<td>0.65</td>
<td>1.10 (0.44 to 2.72)</td>
<td>0.84</td>
<td>1.27 (0.94 to 1.71)</td>
<td>0.12</td>
</tr>
<tr>
<td>Leflunomide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-current use</td>
<td>31 (84)</td>
<td>343 (94)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
<td>185 (88)</td>
<td>1977 (96)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Current use</td>
<td>6 (16)</td>
<td>20 (6)</td>
<td>3.50 (1.28 to 9.60)</td>
<td>0.01</td>
<td>4.02 (1.08 to 15.0)</td>
<td>0.04</td>
<td>3.05 (1.92 to 4.85)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-current use</td>
<td>NR</td>
<td>343 (94)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
<td>199 (94)</td>
<td>1952 (94)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Current use</td>
<td>20 (6)</td>
<td>19 (36)</td>
<td>1.43 (0.40 to 5.19)</td>
<td>0.58</td>
<td>1.98 (0.40 to 9.78)</td>
<td>0.40</td>
<td>1.01 (0.55 to 1.87)</td>
<td>0.98</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-current use</td>
<td>NR</td>
<td>272 (75)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
<td>147 (70)</td>
<td>1606 (78)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Current use</td>
<td>91 (25)</td>
<td>73 (40)</td>
<td>0.36 (0.13 to 1.05)</td>
<td>0.06</td>
<td>0.17 (0.04 to 0.65)</td>
<td>0.01</td>
<td>1.55 (1.13 to 2.13)</td>
<td>0.007</td>
</tr>
<tr>
<td>High-risk DMARD1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-current use</td>
<td>NR</td>
<td>356 (98)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
<td>199 (94)</td>
<td>2034 (98)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Current use</td>
<td>7 (2)</td>
<td>32 (6)</td>
<td>5.84 (1.46 to 23.4)</td>
<td>0.01</td>
<td>23.0 (2.88 to 184)</td>
<td>0.003</td>
<td>3.25 (1.62 to 6.32)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Low-risk DMARD1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-current use</td>
<td>NR</td>
<td>356 (98)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
<td>NR</td>
<td>2039 (98)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Current use</td>
<td>7 (2)</td>
<td>32 (6)</td>
<td>1.48 (0.16 to 13.6)</td>
<td>0.73</td>
<td>3.43 (0.26 to 45.7)</td>
<td>0.35</td>
<td>1.58 (0.61 to 4.12)</td>
<td>0.35</td>
</tr>
<tr>
<td>NSAID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-current use</td>
<td>26 (70)</td>
<td>219 (60)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
<td>129 (61)</td>
<td>1202 (58)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Current use</td>
<td>11 (30)</td>
<td>144 (40)</td>
<td>0.62 (0.28 to 1.35)</td>
<td>0.23</td>
<td>0.79 (0.30 to 2.06)</td>
<td>0.62</td>
<td>0.90 (0.67 to 1.21)</td>
<td>0.47</td>
</tr>
<tr>
<td>PPI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-current use</td>
<td>NA</td>
<td>NA (52)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>210 (58)</td>
<td>1.0 (ref)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Current use</td>
<td>NA</td>
<td>NA (52)</td>
<td>NA</td>
<td>NA</td>
<td>101 (48)</td>
<td>861 (42)</td>
<td>1.29 (0.97 to 1.72)</td>
<td>0.08</td>
</tr>
</tbody>
</table>

Bolded OR values are statistically significantly different than reference group.
*Adjusted for income, rurality, presence of extra-articular rheumatoid arthritis, other anti-rheumatic medication use, ADGs (aggregated diagnostic groups), and comorbidities (for TB: diabetes and chronic kidney disease, and for NTM: asthma, COPD and gastro-oesophageal reflux disease).
†High-risk DMARDs are a grouping of drugs with high immunosuppressing potential, including cyclophosphamide, azathioprine, ciclosporin, mycophenolate and chlorambucil.
‡Low-risk DMARDs have low immunosuppressing potential and include gold and penicillamine.

anti-TNF, anti-tumour necrosis factor; DMARD, disease modifying anti-rheumatic drug; NA, not assessed; NR, not reportable (in accordance with data use restrictions, cells containing fewer than six individuals cannot be reported); NSAID, non-steroidal anti-inflammatory; NTM, nontuberculous mycobacterial; PPI, proton pump inhibitor; ref, reference group. In accordance with data use restrictions, cells containing fewer than six individuals cannot be reported.

positive predictive value (69.5%–100%). But still might have misclassified some patients with NTM colonisation as having disease, reducing the validity of risk estimates.

In summary, although it is difficult to distinguish risks conferred by anti-rheumatic drugs from disease activity among Ontario seniors with RA, current anti-TNF use is associated with an increased risk of both TB and NTM. Leflunomide and drugs with high immunosuppressing potential are risk factors for both TB and NTM, while high-dose corticosteroids and hydroxychloroquine are risk factors for NTM. Potential approaches and benefits of screening for NTM disease in this population should be investigated.

Author affiliations
1 Joint Division of Respiratory, Department of Medicine, University Health Network and Mount Sinai Hospital, Toronto, Ontario, Canada
2 West Park Healthcare Centre, Toronto, Ontario, Canada
3 Department of Medicine, University of Toronto, Toronto, Ontario, Canada
4 Public Health Ontario, Toronto, Ontario, Canada
5 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
6 Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
7 Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada
8 Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada
9 Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada
10 Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada
11 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
12 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
13 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
14 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
15 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
16 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
17 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
18 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
19 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
20 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

Acknowledgements

We would like to thank the Data Quality and Information Management department at the Institute for Clinical Evaluative Sciences (ICES) for linking the mycobacteria testing data from the Public Health Ontario (PHO) Laboratories to the provincial health administrative data.

Competing interests

None declared.

Funding

The authors acknowledge and thank the Ontario Thoracic Society and the Ontario Lung Association for funding support provided for this research study. This research was also supported by the Institute for Clinical Evaluative Sciences (ICES), a non-profit research institute funded by the Ontario Ministry of Health and Long-Term Care. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred.

Provenance and peer review

Not commissioned; externally peer reviewed.

REFERENCES